Patibandla S A, Dallas J S, Seetharamaiah G S, Tahara K, Kohn L D, Prabhakar B S
Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston 77555-1019, USA.
J Clin Endocrinol Metab. 1997 Jun;82(6):1885-93. doi: 10.1210/jcem.82.6.4020.
To develop a method that can be used to directly detect binding of antibodies to TSH receptor (TSHr), we employed Chinese hamster ovary (CHO) cells permanently transfected with a human TSHr complementary DNA (CHOR). These cells showed increased cAMP production when treated with either human TSH or thyroid-stimulating antibodies and decreased TSH-mediated cAMP production when treated with stimulation-blocking antibodies. We employed flow cytometry and rabbit antibodies against the extracellular domain of the TSHr (ETSHr) to test whether these cells can be used to directly detect and quantitate the binding of anti-TSHr antibodies. Rabbit anti-ETSHr bound specifically to CHOR cells, and the binding could be blocked with purified ETSHr. To test the feasibility of using these cells for epitope mapping, we tested the binding of rabbit antibodies raised against several synthetic TSHr peptides. Rabbit antipeptide 92 (amino acids 12-30) and 91 (amino acids 32-46) showed little or no binding to the CHOR cells. In contrast, antibodies raised against peptides 93 (amino acids 316-330), 95 (aa 325-345), 3A (aa 357-372), 367 (aa 367-386), and 1B (aa 362-376) showed significant binding to the CHOR cells. The specificity of binding of antipeptide antibodies was demonstrated by a complete inhibition of binding by corresponding peptides. When TSH-binding inhibitory Ig-positive sera from 15 patients with hyperthyroidism were tested, 8 of them showed specific binding to the CHOR cells compared to their relative binding to normal CHO cells; sera from all normal individuals tested did not exhibit specific binding to CHOR cells. These studies showed the usefulness of CHOR cells and flow cytometry in epitope mapping using sera with known specificities and the potential usefulness of the technique to detect anti-TSHr antibodies in patient sera.
为开发一种可用于直接检测抗体与促甲状腺激素受体(TSHr)结合的方法,我们使用了稳定转染人TSHr互补DNA(CHOR)的中国仓鼠卵巢(CHO)细胞。这些细胞在用人类促甲状腺激素(TSH)或促甲状腺刺激抗体处理时,细胞内cAMP生成增加;在用刺激阻断抗体处理时,TSH介导的cAMP生成减少。我们使用流式细胞术和针对TSHr胞外域(ETSHr)的兔抗体,来测试这些细胞是否可用于直接检测和定量抗TSHr抗体的结合。兔抗ETSHr特异性结合CHOR细胞,且这种结合可被纯化的ETSHr阻断。为测试使用这些细胞进行表位作图的可行性,我们检测了针对几种合成TSHr肽段产生的兔抗体的结合情况。兔抗肽段92(氨基酸12 - 30)和91(氨基酸32 - 46)与CHOR细胞几乎没有或没有结合。相比之下,针对肽段93(氨基酸316 - 330)、95(氨基酸325 - 345)、3A(氨基酸357 - 372)、367(氨基酸367 - 386)和1B(氨基酸362 - 376)产生的抗体与CHOR细胞有显著结合。相应肽段能完全抑制抗肽段抗体的结合,证明了抗肽段抗体结合的特异性。检测15例甲状腺功能亢进患者的TSH结合抑制性Ig阳性血清时,其中8例与CHOR细胞呈现特异性结合,与其与正常CHO细胞的相对结合情况相比;所有检测的正常个体血清均未显示与CHOR细胞有特异性结合。这些研究表明,CHOR细胞和流式细胞术在使用已知特异性血清进行表位作图方面有用,且该技术在检测患者血清中抗TSHr抗体方面具有潜在用途。